

MVT *in Silico*

London, Canada.

Presenter.

Sanjay R Kharche.

Ph.D.

CEO & scientific officer.

September 2025.

Purpose & approach.

MVT *in Silico* is a life sciences platform company that develops effective medical treatments.

We do that using our timeline compressing
computer modelling & simulation (CM&S), and real
world validated using our **human relevant non-
animal devices**.

Our approach surpasses current industry
standards.

The problem.

Conventional treatment development methods do not provide reliable.

Conventional data is not human relevant:
augmented risk at early clinical trials.

Only 5% drugs are approved.

Subjectively designed experiment R&D:
large avoidable costs of materials, animals, time.

Development cycles are over 15 years, costs ~ \$B.

An opportunity.

Roadmap to reducing Animal Testing in Preclinical Safety Studies (FDA, April 2025).

... The U.S. Food and Drug Administration is taking a groundbreaking step to advance public health ... **with more effective, human relevant methods.** The new approach is designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering research and development (R&D) costs, and ultimately, drug prices.

New Drugs and Clinical Trial Rules (2023) amendment has been passed by the Government of India which aims to replace the use of animals in research, especially in drug testing. (July 2023).

Knowledge (physics) driven is better than purely data driven.

Machine learning/data driven strategies.

ML based virtual screening.

Deep neural networks.

Generative AI.

Convolution neural
networks.

Generative convolution
networks.

Comparatively easier.

< 60% hit confirmation success. †

Knowledge driven strategy † †.

Structure.

Physics based virtual screening.

Molecular docking.

Molecular dynamics:
free energy, conformations.


Not easy to do.

> 95% hit confirmation success. †

† Conscience Consortium cache #1 challenge outcomes. Conscience Symposium. April 2025, Montreal.

† † MVT company's present materials discovery workflow.

Our solution.
A human relevant
biotech platform.



Traction:
Two clients in
phase 1.



Efficacy & safety of
hormonal (peptide)
treatment.

**Welsh Vascular Biology
Laboratory,
Western University.**

Molecular plasticity
under high blood
pressure.

Competition & projection.

	Company.	Age (years)	Revenue.	Raised.	focus/indications
Purely AI/ML					
	Molecular Forecaster.	16	\$5M	Bootstrapped.	Small molecule drug discovery.
	VariationalAI.	6	<u>\$1.6/year.</u>	US\$5.5M (2025)	Oncology.
AI-lab.	VoxCell Bioinnovation.	6	\$3.1M.	CAD\$5M.	Breast cancer.
	Intrepid Labs.	3	\$11M.	US\$11M	Formulations, oncology. Acquired by J Labs.
	In Silico Medicine.	12	US\$30M in 2022	\$123M.	AI & robotic lab, aging & oncology. HKEX IPO filed (2025).

Team.



Dr. SR Kharche.

Founder and scientific officer.

Trained in maths, physics, & computing. Has 30 years of experience in scientific computing, device development, and scientific research.





Prof. D. G. Welsh.

Scientific Advisor.

Director of Welsh Vascular Biology Laboratory, Western University.
World renowned tri-council eligible scientist in pharmacology.

An investment opportunity.
**We are raising
\$1.5M.**



Expected returns
above industry
standards.

Investment ask:	\$1.5M.
Total revenue (EBITDA) at end of 5 years:	\$6.4M.
Exit using 3.4x:	\$21.76M.
At 30% return, \$1.5M grows to	\$5.6M.
Investor ownership:	3.88%.
Discount for convertible notes:	25%.

Key takeaways.

- Future proofed biotech company, timely initiative.
- Tech built ready, primed for growth.
- Return on investment within 7 years.

Contact.

Dr. SR Kharche.

sumus@mvtinsilico.ca

5198780685

<https://www.mvtinsilico.ca>

London Canada.